



MEMORANDUM

To: Kaiser Permanente Network Physicians
Kaiser Permanente Pharmacies

Date: August 13, 2026

Subject: Notice Part D Negative Formulary Change-
Effective September 1st, 2026

As a part of our due diligence to inform all concerned of Medicare Part D Formulary Changes, CMS requests the following notification is for all Providers and pharmacy teams.

Medicare Part D Benefit Coverage – Negative Formulary Change

During the year, Kaiser Permanente may update our Medicare Part D Formulary (Drug List). As a participating Provider in the Kaiser Permanente Part D program, the list below is intended to inform you of these changes.

Effective September 1st, 2026, the following changes will take place to KP Medicare Part D Formulary:

➤ Formulary Product Removal and Replacement

Brand name drugs:

- Xeljanz Tabs (5 mg, 10 mg), Tier 5 to be replaced with generic Tofacitinib Citrate Tabs (5 mg, 10 mg), Tier 2
- Xeljanz Soln 1 mg/mL to be replaced with generic Tofacitinib Citrate Soln 1 mg/mL, Tier 4
- Xeljanz XR Tb24 11 mg, Tier 5 to be replaced with generic Tofacitinib Citrate ER Tb24 11 mg, Tier 2
- Xeljanz XR Tb24 22 mg, Tier 5 to be replaced with generic Tofacitinib Citrate ER Tb24 22 mg, Tier 5

This change applies to new starts only. Affected members will be grandfathered unless they were prescribed the new product before the effective date.

Medicare Part D negative formulary changes for calendar year 2026 are listed below.

Reason for change	Drug Name/Description	Date and Type of Change:	Alternate Drug (Note: Medicare Part D benefit does not cover Over the counter (OTC) drugs)
Generic Available	Xeljanz Tabs (5 mg, 10 mg)	September 1, 2026 Brand drug to be replaced with generic	Tofacitinib Citrate Tabs (5 mg, 10 mg)
Generic Available	Xeljanz Soln 1 mg/mL	September 1, 2026 Brand drug to be replaced with generic	Tofacitinib Citrate Soln 1 mg/mL
Generic Available	Xeljanz XR Tb24 (11 mg, 22 mg)	September 1, 2026 Brand drug to be replaced with generic	Tofacitinib Citrate ER Tb24 (11 mg, 22 mg)



Generic Available	TAZORAC CREA 0.05 %	August 1, 2026 Brand drug to be replaced with generic	TAZAROTENE CREA 0.05 %
Generic Available	EDURANT TABS 25 MG	August 1, 2026 Brand drug to be replaced with generic	RILPIVIRINE HCL TABS 25 MG
Generic Available	ATROVENT HFA AERS 17 MCG/ACT	August 1, 2026 Brand drug to be replaced with generic	IPRATROPIUM BROMIDE HFA AERS 17 MCG/ACT
Generic Available	OFEV CAPS 100 MG, 150 MG	July 1, 2026 Brand drug to be replaced with generic	NINTEDANIB ESYLATE CAPS 100 MG, 150 MG
Generic Available	FARXIGA TABS 5 MG, 10 MG	July 1, 2026 Brand drug to be replaced with generic	DAPAGLIFLOZIN TABS 5 MG, 10 MG
Generic Available	Briviact tabs 10mg, 25 mg, 50 mg, 75 mg, 100 mg and Soln 10mg/mL	June 1 st , 2026 Brand drug replaced with generic	Brivaracetam TABS (10 mg, 25 mg, 50 mg, 75 mg, 100 mg and Soln 10mg/mL
Biosimilar Available	Novolog Soln 100 Units/mL	June 1 st , 2026 Original biological product replaced with biosimilar	Kirsty SOLN (100 UNIT/mL),
Biosimilar Available	Novolog Flexpen 100 Units/mL	June 1 st , 2026 Original biological product replaced with biosimilar	Kirsty SOPN (100 UNIT/mL),
Generic Available	POMALYST CAPS 1 MG, 2 MG, 3 MG, 4 MG	May 1, 2026 Brand drug replaced with generic	POMALIDOMIDE CAPS 1 MG, 2 MG, 3 MG, 4 MG
Generic Available	SPRITAM TB3D 250 MG, 500 MG	May 1, 2026 Brand drug replaced with generic	LEVETIRACETAM TB3D 250 MG, 500 MG
Generic Available	Gleostine CAPS 10 mg, 40 mg, 100 mg	February 1, 2026 Brand drug replaced with generic	Lomustine CAPS 10 mg, 40mg, 100 mg



**KAISER
PERMANENTE®**

MEMORANDUM

Generic Available	Tracleer TBSO 32 mg	February 1, 2026 Brand drug replaced with generic	Bosentan TBSO 32 mg
Generic Available	Xarelto TABS 2.5 mg	February 1, 2026 Brand drug replaced with generic	Rivaroxaban TABS 2.5 mg